Who are azathioprine or adalimumab and infliximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azathioprine-or-adalimumab-and-infliximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

azathioprine or adalimumab and infliximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

azathioprine or adalimumab and infliximab (azathioprine or adalimumab and infliximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant combination (purine analog + TNF-α inhibitors). Area: Immunology / Rheumatology.

phase 3 Immunosuppressant combination (purine analog + TNF-α inhibitors) TPMT/HGPRT (azathioprine); TNF-α receptor (adalimumab and infliximab) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

azathioprine or adalimumab and infliximab (azathioprine or adalimumab and infliximab) — Tokyo Medical and Dental University. This is a combination therapy using azathioprine (an immunosuppressant) alongside TNF-alpha inhibitors (adalimumab and/or infliximab) to suppress immune-mediated inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
azathioprine or adalimumab and infliximab TARGET	azathioprine or adalimumab and infliximab	Tokyo Medical and Dental University	phase 3	Immunosuppressant combination (purine analog + TNF-α inhibitors)	TPMT/HGPRT (azathioprine); TNF-α receptor (adalimumab and infliximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant combination (purine analog + TNF-α inhibitors) class)

Tokyo Medical and Dental University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). azathioprine or adalimumab and infliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/azathioprine-or-adalimumab-and-infliximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab